Executive summary. Cannabinoids are a family of compounds produced by Cannabis sativa and, in some cases, manufactured synthetically or semi-synthetically. The most familiar are THC and CBD, but the plant contains many related compounds whose abundance, pharmacology and evidence differ. A pharmaceutical understanding requires accurate terminology, analytical control and caution around claims.
Acidic and neutral cannabinoids
Fresh cannabis predominantly contains acidic precursors such as THCA, CBDA and CBGA. Heat and time promote decarboxylation to THC, CBD and CBG. Analytical reports should state whether acidic and neutral forms are measured separately and how any total-cannabinoid calculation is performed.
Acidic cannabinoids are frequently the majority species in raw or lightly processed material, so a specification based only on the neutral forms can understate the total cannabinoid content and mislead potency comparisons between products.
THC
Delta-9-tetrahydrocannabinol is the principal intoxicating cannabinoid in most drug-type cannabis. Its clinical effects, impairment risk and controlled status depend on dose, route and patient factors. In pharmaceutical products, THC requires precise assay, uniformity, stability and patient-use controls.
THC quantification errors most often arise from confusing total THC (accounting for decarboxylation potential) with as-is THC — the two figures serve different purposes and should never be used interchangeably on a label or specification.
CBD
Cannabidiol is not generally intoxicating and is used in an authorised medicine for specific seizure disorders. Commercial CBD products should not be assumed equivalent to authorised pharmaceutical cannabidiol. Purity, dose, interactions and evidence matter.
CBD’s regulatory treatment varies significantly across jurisdictions depending on THC co-content and intended use, meaning a single European cannabinoid specification will rarely satisfy every target market without country-specific review.
CBG and CBC
Cannabigerol and cannabichromene are usually present at lower concentrations. CBG is linked biosynthetically to the precursor CBGA. Research interest does not yet justify broad therapeutic claims. These compounds may be controlled as markers or defined constituents in extracts.
CBG and CBC remain under-characterised clinically relative to their growing commercial visibility; specifications should document their presence accurately without implying a therapeutic evidence base that does not yet exist.
CBN
Cannabinol can increase as THC oxidises. It may therefore serve as a stability or degradation indicator. Claims that CBN is proven as a sleep aid exceed the available evidence.
CBN’s presence is frequently a stability signal rather than an intentional formulation choice — an unexpectedly high CBN reading in a THC-dominant product should trigger a degradation investigation, not just a specification note.
THCV and CBDV
THCV and CBDV are propyl homologues of THC and CBD. They occur in selected chemotypes and are usually present at lower concentrations. Their analytical separation and clinical evidence require dedicated assessment.
THCV and CBDV remain minor constituents in most cannabis chemotypes, and analytical methods should be checked for adequate sensitivity and selectivity at the low concentrations typically encountered.
Analytical and regulatory implications
A product should define which cannabinoids are active, markers, impurities or degradation products. Specifications and methods should follow that role. A broad 'full-spectrum' label is not a substitute for characterisation.
Taken together, a defensible cannabinoid specification separates acidic and neutral forms, states the analytical method and its validation status, and avoids conflating commercial novelty with an established evidence base.
Practical reference table
| Cannabinoid | Common precursor | Intoxicating potential | Key quality issue |
|---|---|---|---|
| THC | THCA | Yes, dose dependent | Assay, uniformity and oxidation |
| CBD | CBDA | Generally no | Purity, dose and interactions |
| CBG | CBGA | Generally no | Low-level quantification |
| CBN | Often increases from THC oxidation | Low/uncertain | Stability indicator |
| CBC | CBCA | Generally no | Analytical selectivity |
| THCV | THCVA | Dose/context dependent | Low abundance and evidence limits |
| CBDV | CBDVA | Generally no | Reference standards and sensitivity |
Decision and implementation path
Common implementation mistakes
Common mistakes include choosing a country because cultivation appears attractive without confirming product access; assuming that GMP certification resolves controlled-drug permissions; using broad cannabis terminology where the active substance is not clearly defined; and relying on commercial claims that exceed the available evidence. A second recurring weakness is treating laboratories, logistics providers or cultivators as external to the pharmaceutical quality system. Outsourced work remains part of the regulated supply chain and requires qualification, agreements, performance review and change notification.
Frequently asked questions
What is total THC?
A calculated value combining THC with the molar equivalent of THCA, using a defined conversion factor.
Is CBD always safe because it is non-intoxicating?
No. Dose, interactions, liver effects and product quality still matter.
Is CBN proven to improve sleep?
Current evidence is insufficient for broad claims.
Why measure acidic cannabinoids?
They are major constituents of the plant and can convert during processing or analysis.
Are minor cannabinoids regulated separately?
Their treatment depends on product classification, claims and national law.
Primary references and guidance
- EMA: Cannabis-derived medicinal product terminology
- European Pharmacopoeia, Cannabis flower
- European Pharmacopoeia, Cannabidiol
- ICH Q2(R2)
- ICH Q14
- EU GMP Part I, Chapter 6
- EMA EPAR for Epidyolex
- Peer-reviewed pharmacology literature
Confirm the current effective version and national applicability before operational, medical or regulatory use.